このエントリーをはてなブックマークに追加
ID 59958
JaLCDOI
フルテキストURL
Thumnail 74_3_245.pdf 1.92 MB
著者
Yamamoto, Shumpei Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takayama, Hiroshi Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Shimodate, Yuichi Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Takezawa, Rio Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Nishimura, Naoyuki Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Doi, Akira Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Mouri, Hirokazu Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Matsueda, Kazuhiro Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Mizuno, Motowo Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Okada, Hiroyuki Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID researchmap
抄録
Antithrombotic therapy is a major risk factor for delayed bleeding after endoscopic submucosal dissection (ESD) for gastric neoplasia. A potassium-competitive acid blocker, vonoprazan, is expected to prevent delayed bleeding better than conventional proton pomp inhibitors (PPIs), but the evidence is controversial. We sought to clarify the efficacy of vonoprazan for prevention of delayed bleeding after gastric ESD in patients under antithrombotic therapy. We prospectively registered 50 patients who underwent gastric ESD while receiving antithrombotic therapy and vonoprazan in our institution between October 2017 and September 2018. The incidence of delayed bleeding was compared with that in a historical control group of 116 patients treated with conventional PPI. We also evaluated risk factors associated with delayed bleeding. Delayed bleeding was observed in 8 of 50 patients (16.0%), which was not dissimilar from the incidence in the historical control group (12.1%) (p=0.49). In the univariate analysis, age (> 70 years) (p=0.034), multiple antithrombotic drug use (p<0.01), procedure time (> 200 min) (p=0.038) and tumor size (> 40 mm) (p<0.01) were associated with delayed bleeding after gastric ESD, but vonoprazan was not (p=0.49). Vonoprazan may not be more effective than conventional PPIs in preventing delayed bleeding after gastric ESD in patients receiving antithrombotic therapy.
キーワード
vonoprazan
endoscopic submucosal dissection
antithrombotic drug
gastric cancer
Amo Type
Original Article
発行日
2020-06
出版物タイトル
Acta Medica Okayama
74巻
3号
出版者
Okayama University Medical School
開始ページ
245
終了ページ
250
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2020 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID